(Q54272083)

27 May 2018

title

Fluoroquinolone (Lomefloxacin) International Surveillance Trial: a report of 30 months of monitoring in vitro activity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1316072

12 September 2022

Fluoroquinolone (Lomefloxacin) International Surveillance Trial: A report of 30 months of monitoring in vitro activity (English)

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

4 December 2023

author name string

R. N. Jones

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1316072

12 September 2022

language of work or name

English

0 references

publication date

1 April 1992

1 reference

27 May 2018

6 April 1992

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1316072

full work available at URL

12 September 2022

https://api.elsevier.com/content/article/PII:0002934392903108?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

https://api.elsevier.com/content/article/PII:0002934392903108?httpAccept=text/plain

4 December 2023

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

American Journal of Medicine

4 December 2023

published in

1 reference

27 May 2018

volume

92

1 reference

27 May 2018

issue

4A

1 reference

27 May 2018

page(s)

52S-57S

1 reference

27 May 2018

In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

In vitro and in vivo activity of NY-198, a new difluorinated quinolone

4 December 2023

2

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing.

4 December 2023

3

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

Comparative antibacterial activity of new quinolone-carboxylic acid derivatives

4 December 2023

4

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents

4 December 2023

5

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

In vitro activity of lomefloxacin (SC 47111 or NY-198) against isolates of Legionella spp.

4 December 2023

6

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

In vitro activity of lomefloxacin (NY-198 or SC 47111), ciprofloxacin, and erythromycin against 100 clinical Legionella strains.

4 December 2023

7

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

In vitro activity of lomefloxacin against Chlamydia trachomatis, Neisseria gonorrhoeae, Haemophilus ducreyi, Mycoplasma hominis, and Ureaplasma urealyticum

4 December 2023

8

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

In vitro activities of T-3262, NY-198, fleroxacin (AM-833; RO 23-6240), and other new quinolone agents against clinically isolated Chlamydia trachomatis strains

4 December 2023

9

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

In vitro activity of lomefloxacin (SC 47111 or NY-198) against Chlamydia trachomatis strains

4 December 2023

10

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

In vitro activity of lomefloxacin as compared with ciprofloxacin

4 December 2023

11

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses

4 December 2023

12

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

A ten-laboratory study of lomefloxacin (NY-198 or SC 47111) antimicrobial activity in Argentina.

4 December 2023

16

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

Lomefloxacin activity against 2,813 clinical isolates: a collaborative study at three medical centers in Brazil.

4 December 2023

17

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

Lomefloxacin, a new difluoroquinolone: in vitro activity against gram-positive and gram-negative bacteria

4 December 2023

18

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

In vitro evaluation of lomefloxacin activity in Colombia

4 December 2023

19

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

In vitro activity of lomefloxacin (NY-198 or SC 47111).

4 December 2023

20

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

In vitro antimicrobial activity and postantibiotic effect of lomefloxacin, a new difluoroquinolone.

4 December 2023

21

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

Evaluation of in vitro antimicrobial activity of lomefloxacin against staphylococci, enterococci, Enterobacteriaceae, and Pseudomonas aeruginosa.

4 December 2023

22

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

Comparative in vitro activity of lomefloxacin, a difluoro-quinolone

4 December 2023

23

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

Lomefloxacin (SC 47111 or NY-198), a new difluorinated quinolone: comparison of the in vitro activity with other broad spectrum antimicrobials against Enterobacteriaceae, Acinetobacter spp, Aeromonas spp, and Pseudomonas aeruginosa

4 December 2023

24

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

In vitro activity of lomefloxacin against multiply resistant Pseudomonas aeruginosa, Enterobacter cloacae, and Staphylococcus epidermidis.

4 December 2023

25

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

In vitro activity of lomefloxacin (SC 47111 or NY-198), a new quinolone antimicrobial, against clinical isolates of common pathogens

4 December 2023

26

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

Bactericidal activity of lomefloxacin SC 47111 (NY-198) and ciprofloxacin against selected pathogens.

4 December 2023

27

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

Comparative in vitro activity of lomefloxacin (SC 47111 or NY-198) against fresh clinical bacterial isolates

4 December 2023

28

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

Antimicrobial activity of lomefloxacin (NY-198, SC 47111) against bacterial strains from Venezuela.

4 December 2023

29

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

Aspects of Chemistry in the Development of 4-Quinolone Anti- S2 bacterial Agents

4 December 2023

30

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

The frequency of in-vitro resistance development to fluoroquinolones and the use of a murine pyelonephritis model to demonstrate selection of resistance in vivo

4 December 2023

31

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis

4 December 2023

32

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis

4 December 2023

33

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe

4 December 2023

34

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

In vitro emergence of quinolone-resistant mutants of Escherichia coli, Enterobacter cloacae, and Serratia marcescens

4 December 2023

35

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin

4 December 2023

36

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

Quinolone antimicrobial agents: adverse effects and bacterial resistance

4 December 2023

38

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

Bacterial resistance to quinolones: mechanisms and clinical importance.

4 December 2023

39

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

Prevalence of fluoroquinolone-resistant bacterial isolates in four medical centers during the first quarter of 1990.

4 December 2023

41

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90310-8

4 December 2023

Identifiers

1 reference

27 May 2018

release_27xanynqp5bhhbxtvslkfnn6ga

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/27xanynqp5bhhbxtvslkfnn6ga

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

27 May 2018